PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 47 filers reported holding PROQR THRAPEUTICS N V in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,295 | -19.8% | 10,996 | 0.0% | 0.00% | – |
| Q2 2023 | $17,814 | -23.9% | 10,996 | 0.0% | 0.00% | – |
| Q1 2023 | $23,421 | -42.4% | 10,996 | 0.0% | 0.00% | – |
| Q4 2022 | $40,685 | +408.6% | 10,996 | 0.0% | 0.00% | – |
| Q3 2022 | $8,000 | -11.1% | 10,996 | 0.0% | 0.00% | – |
| Q2 2022 | $9,000 | -10.0% | 10,996 | 0.0% | 0.00% | – |
| Q1 2022 | $10,000 | -88.6% | 10,996 | 0.0% | 0.00% | – |
| Q4 2021 | $88,000 | -4.3% | 10,996 | 0.0% | 0.00% | – |
| Q3 2021 | $92,000 | +24.3% | 10,996 | 0.0% | 0.00% | – |
| Q2 2021 | $74,000 | +1.4% | 10,996 | 0.0% | 0.00% | – |
| Q1 2021 | $73,000 | +58.7% | 10,996 | 0.0% | 0.00% | – |
| Q4 2020 | $46,000 | -13.2% | 10,996 | 0.0% | 0.00% | – |
| Q3 2020 | $53,000 | -27.4% | 10,996 | -8.3% | 0.00% | – |
| Q2 2020 | $73,000 | +12.3% | 11,996 | 0.0% | 0.00% | – |
| Q1 2020 | $65,000 | -45.4% | 11,996 | 0.0% | 0.00% | – |
| Q4 2019 | $119,000 | +88.9% | 11,996 | +9.1% | 0.00% | – |
| Q3 2019 | $63,000 | -37.0% | 10,996 | 0.0% | 0.00% | – |
| Q2 2019 | $100,000 | -34.6% | 10,996 | 0.0% | 0.00% | – |
| Q1 2019 | $153,000 | -12.1% | 10,996 | 0.0% | 0.00% | – |
| Q4 2018 | $174,000 | -24.0% | 10,996 | -7.0% | 0.00% | – |
| Q3 2018 | $229,000 | +126.7% | 11,826 | -14.5% | 0.00% | – |
| Q2 2018 | $101,000 | -12.9% | 13,826 | -63.3% | 0.00% | – |
| Q1 2018 | $116,000 | -4.9% | 37,626 | 0.0% | 0.00% | – |
| Q4 2017 | $122,000 | -41.9% | 37,626 | -13.0% | 0.00% | – |
| Q3 2017 | $210,000 | +191.7% | 43,226 | +212.6% | 0.00% | – |
| Q2 2017 | $72,000 | +33.3% | 13,826 | +27.7% | 0.00% | – |
| Q1 2017 | $54,000 | +1.9% | 10,826 | 0.0% | 0.00% | – |
| Q4 2016 | $53,000 | -27.4% | 10,826 | -1.6% | 0.00% | – |
| Q3 2016 | $73,000 | +87.2% | 11,006 | +36.4% | 0.00% | – |
| Q2 2016 | $39,000 | -25.0% | 8,071 | -23.6% | 0.00% | – |
| Q1 2016 | $52,000 | +73.3% | 10,571 | +206.0% | 0.00% | – |
| Q4 2015 | $30,000 | -16.7% | 3,455 | +38.2% | 0.00% | – |
| Q3 2015 | $36,000 | +44.0% | 2,500 | +66.7% | 0.00% | – |
| Q2 2015 | $25,000 | – | 1,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 1,237,400 | $5,197,000 | 1.55% |
| Prosight Management, LP | 255,000 | $1,071,000 | 0.50% |
| RTW INVESTMENTS, LP | 5,009,768 | $21,041,000 | 0.35% |
| Kerrisdale Advisers, LLC | 453,182 | $1,903,000 | 0.15% |
| Artal Group S.A. | 1,196,218 | $5,024,000 | 0.11% |
| COWEN AND COMPANY, LLC | 285,696 | $1,200,000 | 0.11% |
| Golden Green, Inc. | 16,999 | $71,000 | 0.07% |
| APOGEM CAPITAL LLC | 15,855 | $67,000 | 0.04% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,550,062 | $19,110,000 | 0.04% |
| ALTRINSIC GLOBAL ADVISORS LLC | 241,360 | $1,014,000 | 0.03% |